Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies
NCT06351527
Recruiting
Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ICP-248 as monotherapy or in combination with anti-CD20 monoclonal antibody in Mature B-cell Malignancies
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: BRCR Medical Center, Plantation, Florida +7 locations
Conditions: Mature B-cell Malignancies
Register for Updates
Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
NCT06358651
Recruiting
This U.S. Phase 3 clinical trial is designed to evaluate the efficacy, safety, and tolerability of the acute intranasal (i.n.) administration of Fasedienol Nasal Spray (fasedienol) (3.2 µg) to relieve symptoms of acute anxiety in adult subjects ages 18 through 65 with Social Anxiety Disorder induced by a public speaking challenge (PSC) in a clinical setting. In addition, safety and tolerability of i.n. administration of 3.2 µg of fasedienol, as-needed, up to 6 times per day for up to 12 months,... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2025
Locations: Vistagen Clinical Site, Phoenix, Arizona +23 locations
Conditions: Social Anxiety Disorder
Register for Updates
A Phase 1, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety, Pharmacokinetics, Dosimetry and Biodistribution of GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy Volunteers
NCT06398730
Recruiting
This is a Phase 1, single-center, open-label, single-arm, dose-escalation positron emission tomography study to assess the safety and tolerability, immunogenicity, Pharmacokinetics, dosimetry, and biodistribution after GEH200521 (18F) Injection is co-administered with GEH200520 Injection in healthy volunteers. The estimated study duration for each subject is approximately 28 days in part A and 34 days in part B. The primary study objective is to evaluate the safety and tolerability of the IMPs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Healthy Volunteers
Register for Updates
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
NCT06401356
Recruiting
The purpose of this study is to evaluate the long-term safety and the clinical benefit of pelabresib in patients with hematological and/or solid tumor indications or advanced malignancies. Additionally, participants previously enrolled in studies with pelabresib who received placebo or participants who discontinued pelabresib (for any other reason than participating in this extension study), may be enrolled in this extension study to evaluate the survival and leukemia-free survival (for patients... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Hematologic Malignancy/Stem (Department of Medicine, Division of Hematology/Oncology), Los Angeles, California +14 locations
Conditions: Hematologic Malignancy, Solid Tumor, Advanced Malignancies
Register for Updates
STARLITE for Unresectable High-Grade Gliomas
NCT06428045
Recruiting
The purpose of this study is to determine whether newly diagnosed high-grade glioma(s) that cannot be removed surgically change as a result of the study treatment; and to identify and evaluate the potential side effects (good and bad) of the study treatment in patients with newly diagnosed high-grade glioma(s) that cannot be removed surgically.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: University of Miami, Miami, Florida
Conditions: High Grade Glioma
Register for Updates
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
NCT06435351
Recruiting
This is a pilot protocol to evaluate the safety, feasibility, and immunogenicity of a personalized breast cancer vaccine based utilizing whole exome sequencing data of a patient's residual breast tumor following neoadjuvant chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Moffitt Cancer Center, Tampa, Florida
Conditions: Breast Cancer, Triple Negative Breast Cancer
Register for Updates
Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL
NCT06468202
Recruiting
The overall goal of this large, pragmatic, comparative effectiveness trial is to test the hypothesis that among at-risk individuals, 162 mg/day aspirin is superior to 81 mg/day in preventing Hypertensive disorders of pregnancy (HDP), and that there are multiple factors associated with adherence with aspirin therapy that will be important to identify to enable optimal implementation of study findings and population-level benefits.
Gender:
FEMALE
Ages:
Between 14 years and 35 years
Trial Updated:
06/17/2025
Locations: Cedars Sinai Medical Center, Los Angeles, California +11 locations
Conditions: Hypertensive Disorders of Pregnancy, Preeclampsia, Gestational Hypertension
Register for Updates
Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer
NCT06497569
Recruiting
The purpose of this study is to determine how the STRONG intervention compares with usual care for reducing malnutrition among gastroesophageal cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Moffitt Cancer Center, Tampa, Florida +1 locations
Conditions: GastroEsophageal Cancer
Register for Updates
To Validate Point Mini User Needs
NCT06504667
Recruiting
The objective of the device feasibility study will be to validate the user needs of the Point Mini system. This study will be a single group intervention model where one group of 5 children with partial-hand upper limb loss will be asked to perform several tasks. Successful completion of a task results in a fulfilled user need. Failure to complete a task results in an unfulfilled user need.
Gender:
ALL
Ages:
Between 5 years and 15 years
Trial Updated:
06/17/2025
Locations: University of Colorado Denver | Anschutz Medical Campus, Aurora, Colorado +1 locations
Conditions: Amputation; Traumatic, Hand, Amputation, Congenital
Register for Updates
A Novel Imaging Modality to Evaluate Radiation-Induced Uterine Injury
NCT06518174
Recruiting
The goal of this pilot study is to assess the ability of a new imaging modality, shear-wave-elastography (SWE) and magnetic resonance imaging (MRI) to identify radiation-induced uterine injury (RIUI). The investigator will recruit female patients treated for colorectal or anal cancer at 15 to 39 years with ≥ 50 Gy pelvic radiation (PRT) at least 12 months prior to study initiation.
Gender:
FEMALE
Ages:
Between 15 years and 40 years
Trial Updated:
06/17/2025
Locations: University of Colorado, Aurora, Colorado
Conditions: Uterine Injury
Register for Updates
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
NCT06529822
Recruiting
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and capable of generating measurable neoantigen-specific T-cell responses enabling ctDNA clearance. The personalized cancer vaccines are composed of synthetic long peptides corresponding to prioritized cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/17/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Muscle-Invasive Bladder Carcinoma
Register for Updates
GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder
NCT06547489
Recruiting
The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The main questions it aims to answer are: Does GATE-251 reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no GATE-251)? What medical problems are observed in participants who take GATE-251? Participants will take one tablet of GATE-251 or placebo every week for 6 weeks. Participants w... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
06/17/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +30 locations
Conditions: Major Depressive Disorder
Register for Updates